By: IPP Bureau
Last updated : April 17, 2022 6:34 pm
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Jubilant Ingrevia announced a CDMO contract for an estimated value of Rs 270 crore in the specialty chemicals business, spanning over a period of three years with one of its international customers, who are among the top 10 leading innovator pharmaceutical companies globally.
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer. Both these products involve 7 steps of specialised chemistry. The company was awarded these CDMO projects a few years ago and with extensive work in R&D and scale-up, it has successfully demonstrated its capability in process development, optimisation and scaling-up of complex chemistries. Commercial supplies of both these products will start from FY'23 onwards.
Speaking on the occasion, Rajesh Srivastava, CEO & Managing Director, Jubilant Ingrevia shared, "The pursuit of growth is one of the key features of our strategy. Today's announcement is in line with our strategy & commitment to grow our CDMO business of value-added GMP & Non GMP intermediates. The success of these two GMP intermediates further demonstrates our capabilities to successfully develop and commercialise cost-effective processes with excellent quality involving complex chemistries. Our CDMO project pipeline for our pharmaceuticals & agrochemical continues to be strong and we stay committed to further strengthening our presence in the CDMO business, through a comprehensive and planned capex."